PremiumThe FlyPliant Therapeutics reports Q1 EPS (92c), consensus (75c) Pliant Therapeutics to reduce workforce by 45% Pliant Therapeutics Announces Major Workforce Reduction PremiumThe FlyPliant Therapeutics adopts limited duration stockholder rights agreement Biotech Alert: Searches spiking for these stocks today Biotech Alert: Searches spiking for these stocks today PremiumRatingsCautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization